There are Data show that, for metastatic breast cancer women protein
bound paclitaxel (AbraxaneR injection) compared with the highest standards of
docetaxel dose, the former prolongs investigator assessed time and progression
free survival (PFS) in recent 7 months.
Nab-paclitaxel is a new type of protein bound
paclitaxel, an accepted chemotherapy drugs, combined with albumin, a protein is
very small. Results from a phase II clinical trial, this study enrolled 302
patients with previously untreated metastatic breast cancer patients, published
today in the Journal of Clinical Oncology (JCO).
“We believe that the results
suggest that in the first-line treatment of metastatic breast cancer,
nab-paclitaxel once a week may be more effective and secure than docetaxel once
3 weeks, "lead researcher Dr. Gradisha William J. breast oncology and the Northwestern University
The study included patients with metastatic
breast cancer, protein bound paclitaxel in antitumor effect than paclitaxel
solvent. This study is the evaluation of 3 kinds of protein binding efficacy
and safety of paclitaxel scheme
dose (single week regimen vs3 Zhou Fangan), and to examine differences in two
kinds of dose regimens at the highest standard dose and safety. The patients
were randomly divided into accepting protein bound paclitaxel every 3 weeks of
300 mg/m2 (q3w), 100 mg/m2 150 mg/m2
single week, one week, or paclitaxel 100 mg/m2 q3w. Results show that the
protein bound paclitaxel 150 mg/m2 single week therapy, the median PFS than
treatment with paclitaxel to long, the RECIST standard of curative effect
evaluation, combining the research results of radiologists and scholars were
evaluated, respectively for 12.9 months vs7.5 months, p=0.0065, which were 14.6
vs7.8 months, p=0.012.
Through independent radiology review, protein
bound paclitaxel weekly plan the total efficiency (ORR) than paclitaxel high.
The researchers found statistically significant evaluation weekly nab
paclitaxel dose and the difference between paclitaxel dose.
Through research and independent radiologist
review found, accept the weekly dose of protein bound paclitaxel and docetaxel
compared with paclitaxel, protein have obvious disease control rate (DCR). All
nab paclitaxel dose compared with paclitaxel showed a more security side and
toxic reaction.
Dr. Gradishar said the study results support
the early data, namely the protein bound paclitaxel as a suitable alternative
docetaxel choice, as first-line therapy for metastatic breast cancer. The study
was supported by the California
Frankie is the freelance writer for
e-commerce website in the chemistry. Guidechem.com is just a place for you to
look for some chemicals. Our guidechem provide
the most convenient conditions for the international buyers and let these leads
benefit all the business people. Guidechem chemical B2B network provides
information on china and global chemical market quotation and relative chemical
Information. Guidechem Chemical Network providing the most complete information
of the chemical industry.
没有评论:
发表评论